Adaptive Biotechnologies Corporation
NASDAQ:ADPTBiotechnology
+$0.61 today
- Market cap
- $4.61B
- Beta
- 2.15
- P/E (TTM)
- -54.5
- EPS (TTM)
- -$0.32
Volume 2.21M
Average 1.94M
ADPT Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Adaptive Biotechnologies CorporationNASDAQ: ADPT
Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026
Accounts receivables growth accelerates
Q2 FY2026 accounts receivables of $1.2M (cash outflow) rose 70.7% year over year, ahead of the -39.7% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at -27.5% a year.
Context
- Accounts receivables amounted to 3.1% of revenue in FY2025, up 1.0 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +70.7% holds above the trailing-twelve-month pace of -39.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (8.65M) USD
- Year-over-year change
- -130.9%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (8.65M) | -130.9% |
| FY2024 | 2024-12-31 | (3.74M) | -284.3% |
| FY2023 | 2023-12-31 | 2.03M | +109.0% |
| FY2022 | 2022-12-31 | (22.65M) | -207.6% |
| FY2021 | 2021-12-31 | (7.36M) | — |
Accounts Receivables vs competitors
How ADPT compares with its peers on the latest reported figures
- ADPT's LTM Jun 2026 accounts receivables of $5.23M is the 5th largest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of -39.7% is the 6th highest of 7, against a peer median of +168.0%.
- Accounts receivables amounts to 1.7% of revenue for ADPT, versus a peer median of 5.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $125.44M | +174128.2% | — | 9.2% | |
| LTM Mar 2026 | $59.57M | +453.0% | +151.8% | 10.0% | |
| LTM Sep 2026 | $28.15M | -36.1% | +123.7% | 4.1% | |
| LTM Jun 2026 | $26.3M | +212.9% | — | 5.8% | |
| LTM Jun 2026 | $5.23M | -39.7% | -27.5% | 1.7% | |
| LTM Sep 2026 | $677K | — | — | 118.8% | |
| LTM Jun 2026 | $165K | +123.0% | — | — | |
| LTM Mar 2026 | $0 | -100.0% | — | 0.0% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $0 | — | — | — |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ADPT) | $0 | +168.0% | +137.7% | 5.8% | |
Competitors are the stored peer set for ADPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (207.28M) | (200.19M) | (225.25M) | (159.6M) | (59.5M) |
| Depreciation & Amortization | 13.95M | 20.92M | 22.23M | 19.26M | 17.83M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 53.61M | 51.48M |
| Change in Working Capital | (56.82M) | (71.55M) | (46.18M) | (17.45M) | (57.77M) |
| Accounts Receivables | (7.36M) | (22.65M) | 2.03M | (3.74M) | (8.65M) |
| Inventory | (5.2M) | 817K | (2.84M) | 1.94M | (998K) |
| Accounts Payables | 3.94M | 7.11M | (5.41M) | 671K | 665K |
| Other Working Capital | (48.19M) | (56.83M) | (39.97M) | (16.32M) | (48.79M) |
| Other Non-Cash Items | 57.42M | 66.87M | 92.88M | 8.97M | 1.96M |
| Operating Cash Flow | (192.73M) | (183.95M) | (156.32M) | (95.21M) | (45.99M) |
| Capital Expenditures | (61.75M) | (16.35M) | (10.7M) | (3.66M) | (2.96M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (316.54M) | (278.78M) | (429.56M) | (244.26M) | (181.71M) |
| Sales of Investments | 559.5M | 298.03M | 569.9M | 325.71M | 222.62M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 181.21M | 2.91M | 129.65M | 77.79M | 37.95M |
| Debt Repayment | 0 | 124.38M | 0 | 0 | 0 |
| Common Stock Issued | 26.72M | 7.89M | 2.25M | 241K | 30.4M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 429K | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 27.15M | 132.26M | 2.25M | 241K | 30.4M |
| Effect of Forex Changes | 0 | (260K) | (534K) | 0 | 0 |
| Net Change in Cash | 15.63M | (49.04M) | (24.97M) | (17.18M) | 22.37M |
| Free Cash Flow | (254.47M) | (200.29M) | (167.02M) | (98.88M) | (48.95M) |
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
Intrinsic Alpha fair value
Locked
Current Price
$28.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.